Randomized Prospective Study of Mifepristone in Patients with Endometriosis
Objective To study the clinical efficacy of mifepristone in the treatment of endometriosis. Methods 84 cases of endometriosis patients admitted to Fengxin County People's Hospital from January 2020 to October 2022 were divided into control group and observation group according to random number table method,with 42 cases in each group. The control group was given gestrinone treatment,and the observation group was given mifepristone treatment. The clinical effects,sex hormone levels,tumor markers[carbohydrate antigen (CA125,CA199)],inflammatory cytokines[interleukin-4 (IL-4),interleukin-8 (IL-8),and vascular endothelial growth A(VEGFA) of the two groups were compared. Results The total efficiency in the observation group was significantly higher than that in the control group. After treatment,tumor markers CA125 and CA199 in the 2 groups were lower than before treatment,and the observation group were lower. The inflammatory cytokines IL-4,IL-8 and VEGFA were lower in the 2 groups than before treatment,and the observation group were lower,all the differences were statistically significant (P<0.05). Conclusion Mifepristone has definite clinical effect in the treatment of endometriosis,can effectively inhibit the growth of new blood vessels and the expression of tumor markers. Mifepristone can also regulate the hormone and immune levels.
万方数据
维普
